Cas No.: | 946396-92-5 |
Chemical Name: | HSD-016 |
Synonyms: | C4I13768E1;(2R)-1,1,1-trifluoro-2-[3-[(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl]sulfonylphenyl]propan-2-ol;DB12419;Q27275182;(R)-1,1,1-Trifluoro-2-(3-(((R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-yl)sulfonyl)phenyl)propan-2-ol;Unii-C4I13768E1;HSD-016 |
SMILES: | O[C@](C(F)(F)F)(C)C1=CC=CC(S(=O)(N2[C@H](C)CN(C3=CC=C(F)C=C3C(F)(F)F)CC2)=O)=C1 |
Formula: | C21H21F7N2O3S |
M.Wt: | 514.456868886948 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | HSD-016 (HSD016) is a potent, selective, and efficacious 11β-HSD1 inhibitor with IC50 of 149 and 530 nM for mouse and human 11β-HSD1, respectively; significantly inhibits the 11β-HSD1 activity in mice 3T3-L1 adipocytes with IC50 of 362 nM; HSD-016 (HSD016) has entered phase I clinical trials for the treatment of diabetes. |